VSAR - Versartis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.19
-0.02 (-1.65%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.21
Open1.22
Bid0.00 x 4000
Ask0.00 x 3200
Day's Range1.18 - 1.30
52 Week Range1.14 - 2.55
Volume343,897
Avg. Volume222,807
Market Cap43.126M
Beta (3Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-1.05
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Aravive Biologics and Versartis Complete Merger

    Aravive Biologics, Inc. and Versartis, Inc. (VSAR) announced that the merger of the two companies has closed following Versartis stockholder approval on October 5, 2018. Beginning tomorrow, October 16, 2018, the combined company will operate as Aravive, Inc. and its shares will trade on the Nasdaq Global Select Market under the new ticker symbol “ARAV”.

  • Do You Know Who Else Invests In Versartis Inc (NASDAQ:VSAR)?
    Simply Wall St.2 months ago

    Do You Know Who Else Invests In Versartis Inc (NASDAQ:VSAR)?

    Every investor in Versartis Inc (NASDAQ:VSAR) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owningRead More...

  • Associated Press3 months ago

    Versartis: 2Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 27 cents per share. In the final minutes of trading on Tuesday, the company's shares hit $1.78. A year ago, they were trading at $17.95. _____ ...

  • Versartis Stock and Its Consistent Rise in the Week Ended June 8
    Market Realist5 months ago

    Versartis Stock and Its Consistent Rise in the Week Ended June 8

    Versartis (VSAR) stock rose 48.3% in the week of June 1–8. Versartis had consistent growth during the week, with 6.9% and 9.7% growth on June 4 and June 5, respectively. VSAR stock has risen ~50.9% over the last month. On June 4, Versartis entered into a merger agreement with Aravive Biologics.

  • ACCESSWIRE5 months ago

    Wired News - CHMP Adopted Negative Opinion for Sarepta's EXONDYS in Europe to Treat Patients with Duchenne Muscular Dystrophy

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want access to our free research report on Sarepta Therapeutics, Inc. (NASDAQ: SRPT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SRPT as the Company's latest news hit the wire. On June 01, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion against approval for EXONDYS® (eteplirsen) for treatment of patients with Duchenne muscular dystrophy (DMD).

  • ACCESSWIRE5 months ago

    Free Technical Research on Versartis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).

  • Associated Press6 months ago

    Versartis: 1Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 25 cents per share. The company's shares closed at $1.50. A year ago, they were trading at $17.50. _____ This story was generated by Automated ...

  • GuruFocus.com8 months ago

    Versartis Inc (VSAR) Files 10-K for the Fiscal Year Ended on December 31, 2017

    Versartis Inc (NASDAQ:VSAR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.

  • Associated Press9 months ago

    Versartis posts 4Q profit

    On a per-share basis, the Menlo Park, California-based company said it had net income of 87 cents. The biopharmaceutical company posted revenue of $40,000 in the period. For the year, the company reported ...

  • Are Options Traders Betting on a Big Move in Versartis (VSAR) Stock?
    Zacks9 months ago

    Are Options Traders Betting on a Big Move in Versartis (VSAR) Stock?

    Investors in Versartis (VSAR) need to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRE11 months ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Versartis

    NEW YORK, NY / ACCESSWIRE / December 4, 2017 / It was an exciting day for biotech companies Ampio Pharmaceuticals and Versartis. Both stocks had big closes in the green. Ampio has engaged with LaVoieHealthScience ...

  • TheStreet.comlast year

    Versartis Pops, DBV Wild Ride Continues -- Biotech Movers

    Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.